You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 141 No. 9, September 2005 TABLE OF CONTENTS
  Archives
  •  Online Features
  Study
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (1)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Hematology/ Hematologic Malignancies
 •Leukemias/ Lymphomas
 •Neoplasms
 •Alert me on articles by topic

Treatment of Early-Stage Mycosis Fungoides With Twice-Weekly Applications of Mechlorethamine and Topical Corticosteroids

A Prospective Study

Julie de Quatrebarbes, MD; Eric Estève, MD; Martine Bagot, MD, PhD; Philippe Bernard, MD, PhD; Marie Beylot-Barry, MD, PhD; Michele Delaunay, MD, PhD; Michel D’Incan, MD, PhD; Pierre Souteyrand, MD, PhD; Loïc Vaillant, MD, PhD; Nadège Cordel, MD; Philippe Courville, MD; Pascal Joly, MD, PhD; for the French Study Group of Cutaneous Lymphomas

Arch Dermatol. 2005;141:1117-1120.

Objective  To determine if a therapeutic regimen of twice-weekly applications of mechlorethamine hydrochloride and betamethasone dipropionate cream is effective in the treatment of early-stage mycosis fungoides while increasing cutaneous tolerance.

Design  Prospective nonrandomized study conducted from November 1999 to November 2002.

Setting  Eleven university or hospital dermatology departments in France.

Patients  Sixty-four consecutive patients with newly diagnosed early-stage mycosis fungoides (stage IA, n = 33; stage IB, n = 26; stage IIA, n = 5).

Interventions  Patients were treated with twice-weekly applications of a 0.02% aqueous solution of mechlorethamine followed by an application of betamethasone cream during a 6-month period.

Main Outcome Measures  The primary end point was the rate of complete response during the treatment. Secondary end points were mean delay to achieve complete response, rate of severe cutaneous reactions of intolerance, and rate of relapse after achieving complete response.

Results  Thirty-seven patients (58%) had a complete response after a mean ± SD treatment duration of 3.6 ± 2.5 months: 20 (61%) of 33 patients with stage IA disease, 15 (58%) of 26 patients with stage IB disease, and 2 (40%) of 5 patients with stage IIA disease. Eighteen patients (28%) developed severe cutaneous reactions of intolerance that necessitated treatment discontinuation. Relapse was observed in 17 patients (46%) after a mean ± SD time of 7.7 ± 6.5 months.

Conclusions  A regimen of twice-weekly applications of mechlorethamine and betamethasone cream is an effective treatment for early-stage mycosis fungoides. The decreased frequency of applications provides an advantage to the patient by being easy to use with limited adverse effects.


Author Affiliations: Department of Dermatology and Pathology, University of Rouen, Rouen (Drs de Quatrebarbes, Cordel, Courville, and Joly); and Departments of Dermatology, Orléans General Hospital, Orléans (Dr Estève), University of Créteil, Créteil (Dr Bagot), University of Reims, Reims (Dr Bernard), University of Bordeaux, Pessac (Drs Beylot-Barry and Delaunay), University of Clermont-Ferrand, Clermont-Ferrand (Drs D’Incan and Souteyrand), and University of Tours, Tours (Dr Vaillant); France.
Group Information: Other members of the French Study Group of Cutaneous Lymphomas are listed at the end of this article.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Bifunctional Alkylating Agent-Induced p53 and Nonclassical Nuclear Factor {kappa}B Responses and Cell Death Are Altered by Caffeic Acid Phenethyl Ester: A Potential Role for Antioxidant/Electrophilic Response-Element Signaling
Minsavage and Dillman
J. Pharmacol. Exp. Ther. 2007;321:202-212.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.